Futura Medical partner approved for erectogenic condom manufacture

Advanced transdermal technology-focused healthcare company Futura Medical announced on Thursday that, as anticipated, its regulatory submission to allow TTK Protective Devices to manufacture its erectogenic condom, CSD500, has been approved by the relevant EU Notified Body with an extended shelf life for the product of 18 months.

The AIM-traded firm said TTK, part of the Indian conglomerate TTK Group, is one of Futura's two manufacturing partners for CSD500.

In addition to manufacturing CSD500 for worldwide distribution, TTK will also market and distribute CSD500 in India under its SKORE brand, which is the fastest growing condom brand in India.

A separate regulatory submission, filed after the TTK submission, for the company's European manufacturing partner to manufacture CSD500 with the extended shelf life of 18 months, is also under review with the same relevant body.

Futura said confirmation will be made in due course as to the outcome of that submission.

“At the time of our half year results in September, we highlighted that regulatory approval was imminent for TTK to manufacture CSD500 with an extended shelf life of 18 months,” said CEO James Barder.

“This is in line with the requirements of our commercial partners and we are pleased that this approval has now been received.”

Barder said the company’s manufacturing strategy for CSD500 comprises two manufacturing centres - one in Asia and one in Europe.

“Now that approval for our Asian manufacturer has been received, we will focus on obtaining the approval for our European manufacturer.”